Fate Therapeutics Stock Forecast

Stock Price Forecast

According to 12 analysts polled by S&P Global, Fate Therapeutics stock has a consensus rating of "Buy" and an average price target of $5.41. The average 1-year stock price forecast is 104.92% higher than the current stock price, while the lowest is $2.20 (-16.67%) and the highest is $8.00 (+203.03%).

Price Target: $5.41 (+104.92%)

Analyst Consensus: Buy

Target	Low	Average	Median	High
Price	$2.20	$5.41	$6.00	$8.00
Change	-16.67%	+104.92%	+127.27%	+203.03%

Analyst Ratings

The average analyst rating for Fate Therapeutics stock is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.

Recommendation Trends

Rating	Dec '25	Feb '26	Mar '26	Apr '26	May '26	Jun '26
Strong Buy	5	5	5	4	5	5
Buy	1	1	1	1	1	1
Hold	6	6	6	6	6	6
Sell	0	0	0	0	0	0
Strong Sell	0	0	0	0	0	0
Total	12	12	12	11	12	12

Latest Forecasts

Analyst	Firm	Rating	Rating	Action	Price Target	Upside	Date
Unknown Analyst Mizuho Securities No rating	Mizuho Securities	Buy Maintains $8	Buy	Maintains	$8	+203.03%	Jun 22, 2026
Edward Tenthoff Piper Sandler	Piper Sandler	Buy Reiterates $6	Buy	Reiterates	$6	+127.27%	Jun 9, 2026
Robert Burns H.C. Wainwright	H.C. Wainwright	Buy Reiterates $7	Buy	Reiterates	$7	+165.15%	Jun 8, 2026
Gil Blum Needham	Needham	Hold Maintains n/a	Hold	Maintains	n/a	n/a	Jun 4, 2026
Tazeen Ahmad Bank of America Securities	Bank of America Securities	Hold Reiterates $2 → $2.2	Hold	Reiterates	$2 → $2.2	-16.67%	May 22, 2026

More Analyst Ratings

Financial Forecast

Revenue This Year

5.25M

from 6.65M

-21.05%

from 6.65M

Revenue Next Year

5.24M

from 5.25M

-0.21%

from 5.25M

EPS This Year

-1.03

from -1.15

EPS Next Year

-0.99

from -1.03

Fiscal Year	FY 2021	FY 2022	FY 2023	FY 2024	FY 2025	FY 2026
Period Ending	Dec 31, 2021	Dec 31, 2022	Dec 31, 2023	Dec 31, 2024	Dec 31, 2025	Dec 31, 2026
Revenue	55.85M	96.30M	63.53M	13.63M	6.65M	5.25M
Revenue Growth	77.66%	72.44%	-34.03%	-78.55%	-51.24%	-21.05%
Gross Profit	-159.67M	-224.15M	-93.65M	-104.90M	-85.25M	5.25M
Gross Margin	-285.92%	-232.77%	-147.41%	-769.57%	-1,282.77%	100.00%
Operating Income	-216.99M	-308.39M	-190.51M	-195.54M	-146.60M	-141.29M
Net Income	-212.15M	-281.72M	-160.93M	-186.26M	-136.32M	-132.67M
EPS	-	-	-	-	-1.15	-1.03
Free Cash Flow	-134.71M	-148.77M	-82.31M	-60.77M	-51.56M	-100.67M
No. Analysts	-	-	-	-	-	12

EPS and Forward PE are based on non-GAAP adjusted numbers.

Revenue Forecast

Revenue	2026	2027	2028
High	16.0M
Avg	5.2M
Low	n/a

Revenue Growth

Revenue Growth	2026	2027	2028
High	140.7%
Avg	-21.0%
Low	-100.0%

EPS Forecast

EPS	2026	2027	2028
High	-0.77
Avg	-1.03
Low	-1.21

EPS Growth

EPS Growth	2026	2027	2028
High	-
Avg	-
Low	-